On December 22, Haier Biologics (688139) announced that the company is planning to absorb and merge with Shanghai Raas (002252) through a share swap, issuing A-shares to all shareholders of Shanghai Raas and raising matching funds through the issuance of A-shares. The company's stock is set to be suspended from trading starting December 23 (Monday), with an expected suspension period not exceeding 10 trading days. Haier Biologics stated that during the suspension, the company will actively advance various tasks and, depending on the progress of the matter, will strictly comply with the relevant laws and regulations regarding information disclosure obligations. Once relevant matters are confirmed, the company will promptly release related announcements and apply for the resumption of trading of its stocks. Investors are encouraged to pay attention to subsequent announcements and be cautious about investment risks.

On July 29, Shanghai Raas had previously announced a change in the company's controlling shareholder and actual controller. According to the announcement, Haier Group, through Haier Yinkang (Qingdao) Medical Technology Co., Ltd. (hereinafter referred to as Haier Yinkang), acquired 20% of Shanghai Raas's shares held by Keli Fu for a total price of 12.5 billion yuan. After the completion of the transaction, Haier Yinkang will hold a total of 26.58% voting rights. Following the change of controlling shareholder to Haier Yinkang, the actual controller has changed to Haier Group. Recently, Shanghai Raas expressed that the transformation of Haier Group into the company's actual controller will provide comprehensive support to the company, ensuring its long-term and stable development. Through a group-oriented operational model, advanced management experience will be deeply integrated into the company, helping to enhance its management level and operational efficiency.

It is reported that Shanghai Raas's main business involves the production and sale of blood products, with major products including human serum albumin, intravenous immunoglobulin, specific immunoglobulin, and coagulation factor products, making it one of the largest blood product manufacturers in China.

https://finance.eastmoney.com/a/202412233275241479.html